SLG
IONS icon

Stanley-Laman Group’s Ionis Pharmaceuticals IONS Stock Holding History

Stanley-Laman Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.82M Buy
60,842
+21,536
+55% +$1.62M 0.49% 55
2026
Q1 		$2.95M Buy
39,306
+2,794
+8% +$221K 0.36% 107
2025
Q4 		$2.89M Buy
36,512
+738
+2% +$55.6K 0.37% 104
2025
Q3 		$2.34M Buy
+35,774
New +$1.75M 0.33% 113

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Stanley-Laman Group's IONS Position: Q2 2026 in Review

Stanley-Laman Group increased its Ionis Pharmaceuticals (IONS) stake by 55% in Q2 2026, buying an estimated $1.62M and bringing the position to 60,842 shares worth $4.82M. The position accounts for 0.49% of the portfolio, ranked #55.

Stanley-Laman Group first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Stanley-Laman Group held 60,842 shares of Ionis Pharmaceuticals worth $4.82M as of Q2 2026.
  • Stanley-Laman Group bought 21,536 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.62M.
  • Ionis Pharmaceuticals made up 0.49% of Stanley-Laman Group's portfolio in Q2 2026, its #55 holding.
  • Stanley-Laman Group first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Stanley-Laman Group's 13F filing for Q2 2026, filed 5 Aug 2026.